BACKGROUND: We aimed to compare the clinical data, laboratory findings, and imaging characteristics of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and aquaporin 4 antibody (AQP4)-positive neuromyelitis optica spectrum disorder (NMOSD), as detailed comparative analyses of laboratory data for both diseases are rare. METHODS: Our retrospective study compared the clinical data, laboratory findings, and imaging characteristics of 118 AQP4-positive patients with first-episode NMOSD and 25 patients with first-episode MOGAD. Logistic regression was used to determine the factors that differentiated MOGAD and AQP4-positive NMOSD. RESULTS: There were significant differences in age, symptoms, recurrence rate, laboratory indicators, and imaging examinations between patients with MOGAD and patients with AQP4-positive NMOSD. Patients with MOGAD were younger and had higher levels of uric acid than those with AQP4-positive NMOSD. The proportion of cortical gray matter/juxtacortical white matter lesions was significantly higher in the MOGAD group than in the NMOSD group. Logistic regression revealed that young age [odds ratio (OR) = 0.947, 95% confidence interval (CI) = 0.905-0.99], high uric acid level (OR = 1.016, 95% CI = 1.006-1.027), and cortical gray matter/juxtacortical white matter involvement (OR = 3.889, 95% CI = 1.048-14.442) were significantly related to MOGAD. CONCLUSION: The multivariate analysis of the present study demonstrated that age, uric acid level, and the presence of lesions in the cortical gray matter/juxtacortical white matter can aid in distinguishing patients with AQP4-positive NMOSD from those with MOGAD. These factors may also aid in determining which patients should be tested for antibodies.
BACKGROUND: We aimed to compare the clinical data, laboratory findings, and imaging characteristics of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and aquaporin 4 antibody (AQP4)-positive neuromyelitis optica spectrum disorder (NMOSD), as detailed comparative analyses of laboratory data for both diseases are rare. METHODS: Our retrospective study compared the clinical data, laboratory findings, and imaging characteristics of 118 AQP4-positive patients with first-episode NMOSD and 25 patients with first-episode MOGAD. Logistic regression was used to determine the factors that differentiated MOGAD and AQP4-positive NMOSD. RESULTS: There were significant differences in age, symptoms, recurrence rate, laboratory indicators, and imaging examinations between patients with MOGAD and patients with AQP4-positive NMOSD. Patients with MOGAD were younger and had higher levels of uric acid than those with AQP4-positive NMOSD. The proportion of cortical gray matter/juxtacortical white matter lesions was significantly higher in the MOGAD group than in the NMOSD group. Logistic regression revealed that young age [odds ratio (OR) = 0.947, 95% confidence interval (CI) = 0.905-0.99], high uric acid level (OR = 1.016, 95% CI = 1.006-1.027), and cortical gray matter/juxtacortical white matter involvement (OR = 3.889, 95% CI = 1.048-14.442) were significantly related to MOGAD. CONCLUSION: The multivariate analysis of the present study demonstrated that age, uric acid level, and the presence of lesions in the cortical gray matter/juxtacortical white matter can aid in distinguishing patients with AQP4-positive NMOSD from those with MOGAD. These factors may also aid in determining which patients should be tested for antibodies.
Authors: Shahd H M Hamid; Dan Whittam; Mariyam Saviour; Amal Alorainy; Kerry Mutch; Samantha Linaker; Tom Solomon; Maneesh Bhojak; Mark Woodhall; Patrick Waters; Richard Appleton; Martin Duddy; Anu Jacob Journal: JAMA Neurol Date: 2018-01-01 Impact factor: 18.302
Authors: S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann Journal: Nervenarzt Date: 2018-12 Impact factor: 1.214
Authors: Dean M Wingerchuk; Vanda A Lennon; Claudia F Lucchinetti; Sean J Pittock; Brian G Weinshenker Journal: Lancet Neurol Date: 2007-09 Impact factor: 44.182
Authors: Sven Jarius; Klemens Ruprecht; Brigitte Wildemann; Tania Kuempfel; Marius Ringelstein; Christian Geis; Ingo Kleiter; Christoph Kleinschnitz; Achim Berthele; Johannes Brettschneider; Kerstin Hellwig; Bernhard Hemmer; Ralf A Linker; Florian Lauda; Christoph A Mayer; Hayrettin Tumani; Arthur Melms; Corinna Trebst; Martin Stangel; Martin Marziniak; Frank Hoffmann; Sven Schippling; Jürgen H Faiss; Oliver Neuhaus; Barbara Ettrich; Christian Zentner; Kersten Guthke; Ulrich Hofstadt-van Oy; Reinhard Reuss; Hannah Pellkofer; Ulf Ziemann; Peter Kern; Klaus P Wandinger; Florian Then Bergh; Tobias Boettcher; Stefan Langel; Martin Liebetrau; Paulus S Rommer; Sabine Niehaus; Christoph Münch; Alexander Winkelmann; Uwe K Zettl U; Imke Metz; Christian Veauthier; Jörn P Sieb; Christian Wilke; Hans P Hartung; Orhan Aktas; Friedemann Paul Journal: J Neuroinflammation Date: 2012-01-19 Impact factor: 8.322
Authors: Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker Journal: Neurology Date: 2015-06-19 Impact factor: 9.910
Authors: Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Corinna Trebst; Marius Ringelstein; Orhan Aktas; Alexander Winkelmann; Mathias Buttmann; Alexander Schwarz; Hanna Zimmermann; Alexander U Brandt; Diego Franciotta; Marco Capobianco; Joseph Kuchling; Jürgen Haas; Mirjam Korporal-Kuhnke; Soeren Thue Lillevang; Kai Fechner; Kathrin Schanda; Friedemann Paul; Brigitte Wildemann; Markus Reindl Journal: J Neuroinflammation Date: 2016-09-26 Impact factor: 8.322